
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing nifedipine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing nifedipine are listed in tablet and capsule forms. No finished nifedipine product of any kind is listed in liquid form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Nifedipine is a calcium channel blocker that compounding pharmacies prepare as topical ointments, creams and gels, and as oral liquids, by prescription.
Nifedipine is a dihydropyridine calcium channel blocker. It blocks the channels that let calcium into the muscle cells lining blood vessels, so those vessels relax and widen, which lowers blood pressure and improves blood flow to the heart. Manufactured nifedipine comes as immediate-release capsules and extended-release tablets (Procardia XL, Adalat CC and generics). The extended-release tablets are FDA-approved for vasospastic angina, chronic stable angina and hypertension. No manufactured topical nifedipine exists in the United States. A prescriber might order compounded nifedipine when they want a topical form for a specific area of skin or mucosa, a combination with a local anesthetic in one preparation, or an oral liquid for a patient who cannot swallow tablets. Compounded preparations are not FDA-approved and require a prescription.
The manufactured oral product has no boxed warning. Its label warns of excessive low blood pressure, especially when starting or raising the dose or with beta-blockers, rare worsening of angina or heart attack, and heart failure in people with tight aortic stenosis. Extended-release tablets have caused bowel obstruction in people with narrowed intestines. Do not use nifedipine if you are allergic to it. Avoid grapefruit, which roughly doubles drug levels. Cimetidine, azole antifungals, macrolide antibiotics and HIV protease inhibitors raise nifedipine levels; phenytoin and St. John's wort lower them. Nifedipine can raise digoxin levels. The label advises use in pregnancy only when the benefit justifies the risk. Nifedipine passes into breast milk in low amounts, and LactMed reports no adverse effects in breastfed infants. Common side effects are headache, flushing, dizziness, leg swelling and fast heartbeat. If a side effect is severe or persists, talk to your prescriber or pharmacist.
Nifedipine inhibits voltage-gated L-type calcium channels in vascular smooth muscle and myocardium, reducing peripheral arterial resistance and dilating coronary arteries, with little effect on cardiac conduction. Oral absorption is complete, with first-pass hepatic metabolism through CYP3A4 to inactive metabolites; the extended-release tablet has about 86% relative bioavailability, protein binding is 92% to 98%, and the immediate-release half-life is roughly 4 to 7 hours, prolonged in hepatic impairment. Labeled indications for Procardia XL are vasospastic angina, chronic stable angina and hypertension. Prescribers have ordered compounded topical nifedipine, alone or with lidocaine, for chronic anal fissure, where StatPearls cites meta-analysis data on calcium channel blockers, and oral nifedipine for nipple vasospasm in nursing mothers (LactMed) and Raynaud phenomenon (StatPearls). Dosing and vehicle are per prescriber. Monitoring: blood pressure, heart rate, peripheral edema, and tacrolimus or digoxin levels where relevant. Immediate-release nifedipine should not be given sublingually because of abrupt hypotension. Nifedipine is not a controlled substance.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally